Many bioanalytical methods utilize liquid-liquid extraction (LLE) with non-polar solvents because LLE produces a cleaner extract.

ACQUITY UPLC® I-Class System

In bioanalysis, where the balance between data quality, sensitivity, and productivity must be carefully weighed, the Waters® ACQUITY UPLC® I-Class System provides unprecedented chromatographic performance.

Advantages of Ostro Pass-through Sample Preparation Versus Solid Supported Liquid Extraction (SSLE)

Which would you choose? Read the latest Application note from Waters and get ALL the facts. Learn More

Aeris HPLC/ UHPLC Columns

Core-Shell Technology for Proteins and Peptides. Ultra-High Resolution and Performance on HPLC and UHPLC Systems

Agilent Bond Elut

For over 30 years, Bond Elut has been the most trusted name in solid phase extraction. Years of use by demanding chemists at top companies worldwide have thoroughly documented its many applications and proven its performance. To this day, you will find more literature references for Bond Elut than any other SPE product in the

Agilent Captiva Filtration

Captiva’s unique dual-depth filtration media provides complete removal of precipitated proteins and outstanding resistance to sample clogging, with no loss of analytes. All Captiva components are ultra clean, and rigorously tested to ensure against non-specific binding. With Captiva, your plasma samples are processed quickly and reliably. Captiva is easily automated for enhanced productivity and excellent

Anti-hIgG Fc antibodies for generic PK assays

Bio-Rad offers two antibody clones specific to human IgG Fc that can be used to detect human or humanized therapeutic antibodies in non-human primate samples.

Anti-Idiotypic Antibodies for Anti-Drug Antibody Assays

Latest new products launched – anti-idiotypic antibodies targeting: Eculizumab Nivolumab Pembrolizumab Ranibizumab Vedolizumab Anti-idiotypic antibodies can be generated to bind specifically to one monoclonal antibody drug. A well-designed anti-drug antibody (ADA) assay requires a highly specific reference antibody against which to measure an anti-drug response. For the clinical phases of development it should ideally be

Anti-Idiotypic Antibodies for Pharmacokinetic Assays

Latest new products launched – anti-idiotypic antibodies targeting: Eculizumab Nivolumab Pembrolizumab Ranibizumab Vedolizumab Anti-idiotypic antibodies can be generated to bind specifically to one monoclonal antibody drug. These highly specialized antibodies can be used to set up pharmacokinetic (PK) assays in different formats to measure free or total drug levels in preclinical and clinical samples. Bio-Rad

Antibodies against etanercept

Bio-Rad has developed antibodies against the biotherapeutic protein etanercept, including an antibody that is targeted to the TNFR2(p75)-IgGFc fusion region, enabling detection of etanercept very specifically. The antibodies are ideal for the development of a PK bridging ELISA, and as a reference standard in an ADA assay. They support bioanalytical and therapeutic drug monitoring assays for etanercept and biosimilar products.

Antibodies against ranibizumab

Bio-Rad has developed range of antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A). The recombinant monoclonal anti-ranibizumab antibodies are inhibitory, non-inhibitory, and drug-target complex specific antibodies and designed for use in pharmacokinetic (PK) and immunogenicity assays for

Antibody-Drug Conjugates (ADCs)

With the potential to allow targeted delivery of anticancer drugs to tumors, with minimal impact on normal tissue, there is increasing interest in ADCs in new drug development. The heterogeneity and dynamic nature of ADCs raises unique bioanalytical challenges, which Waters explores in Bioanalysis Zone’s Spotlight on ADCs. Learn how these challenges can be addressed

Application Handbook: Clinical 47 real life applications

Shimadzu has released the first Application Handbook “Clinical”. It contains most advanced technologies and solutions such as chromatography, mass spectrometry, spectroscopy and life sciences instruments.

Ascentis® Express Products by Sigma-Aldrich: Columns for starting a new method and lipid analysis

C18 HPLC Column   Ascentis® Express C18 is the first choice for starting a new method. Ascentis Express HPLC columns, through the use of Fused-Core® particle technology, can provide you with both the high speed and high efficiencies of sub-2 μm particles at lower system pressure. With identical conditions, the Ascentis Express C18 column performs

Ascentis® Express Products by Sigma-Aldrich: Columns that use combined technology

Phenyl-Hexyl HPLC Columns The phenyl phase has unique reversed-phase selectivity, especially for polar aromatics and heterocyclic compounds, arising from solute interaction with the aromatic ring and its delocalized electrons. Ascentis® Express Phenyl-Hexyl is complementary (orthogonal) to both C18 and RP-Amide Ascentis Express phases because of this unique aromaticity. Phenyl phases also tend to exhibit good

Ascentis® Express Products by Sigma-Aldrich: Columns used for analysis of Polar and Non – Polar compounds

HILIC HPLC Columns HILIC chromatography is a variation of normal-phase chromatography with the distinction that one of the major components of the mobile phase is water. The high volatility of the mobile phase makes HILIC LC-MS friendly, and allows for increased MS sensitivity. Many classes of polar compounds can be retained on the Ascentis® Express

Ascentis® Express Products by Sigma-Aldrich: Columns used for seperation of peptides, amines and small proteins

Peptide ES-C18 HPLC Columns   Ascentis® Express Peptide ES-C18 is a high-speed, high-performance liquid chromatography column based on a new 160Å Fused-Core® particle design. As such, Ascentis Express Peptide ES-C18 columns were specifically engineered to separate higher molecular weight compounds; peptides and small proteins for example. Their capacity for larger analytes and exceptional ruggedness make

1 2 3 7